A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.

A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.

Item
http://www.wikidata.org/entity/Q50709215
Best use of experimental data in cancer informaticsChemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumorsExpression of enzymatically inactive wasp venom phospholipase A1 in Pichia pastoris.Synergistic anti-tumor therapy by a comb-like multifunctional antibody nanoarray with exceptionally potent activity.Drug metabolism by tumours: its nature, relevance and therapeutic implications.Use of antibodies and immunoconjugates for the therapy of more accessible cancers.Preclinical evaluation of a novel CEA-targeting near-infrared fluorescent tracer delineating colorectal and pancreatic tumors.Characterization of a fusion protein of RGD4C and the β-lactamase variant for antibody-directed enzyme prodrug therapy.The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment.Antibody-enzyme fusion proteins for cancer therapy.PEGylation and its impact on the design of new protein-based medicines.Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination.Enzyme/Prodrug Systems for Cancer Gene Therapy.Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial.Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo.The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity
P2860

A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.

Item
http://www.wikidata.org/entity/Q50709215
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
A phase I study of single admi ...... s-iodo phenol mustard prodrug.
@en
A phase I study of single admi ...... s-iodo phenol mustard prodrug.
@nl
type
label
A phase I study of single admi ...... s-iodo phenol mustard prodrug.
@en
A phase I study of single admi ...... s-iodo phenol mustard prodrug.
@nl
prefLabel
A phase I study of single admi ...... s-iodo phenol mustard prodrug.
@en
A phase I study of single admi ...... s-iodo phenol mustard prodrug.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
A phase I study of single admi ...... is-iodo phenol mustard prodrug
@en
P2093
P304
P31
P356
10.1158/1078-0432.CCR-06-0769
P407
P433
P478
P50
P577
P698
P921